D rug-eluting stents, introduced to reduce neointimal proliferation and the subsequent clinical restenosis, represent the current mainstay for the treatment of coronary artery stenosis. 1 However, this benefit is paid back with an increased incidence of late stent thrombosis. 2 In addition, the presence of a permanent metallic cage within the arterial wall prevents a full restoration of normal vessel physiology. 3 In the past years, fully bioresorbable vascular scaffolds (BVSs) have emerged as a novel promising approach to treat coronary stenosis by providing transient vessel support with drug delivery capability, 3 without the long-term limitations associated with vessel caging. This technology has the potential to overcome many of the safety concerns associated with drug-eluting stents, with possible clinical benefits. 3 We report the first comprehensive intracoronary imaging study of late clinically driven BVS restenosis, including 3D optical coherence tomography.
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A 72-year-old man with a 70% de novo left circumflex stenosis ( Figure 1A , 1C, and 1D) was treated with a 3.0×18 mm BVS (ABSORB, Abbott Laboratories), deployed through a standard stepwise balloon dilation (2 atm every 5″ up to a 30″ inflation at 16 atm), after predilation with a 3.0×9 mm Maverick balloon (Boston Scientific). A good angiographic result was achieved after postdilation with 3.25×12 mm noncompliant Quantum balloon (Boston Scientific; Figure 1B ). At the time of BVS implantation, the patient was on the following pharmacological therapy: (1) aspirin lysine 75 mg QD;
(2) clopidogrel sulfate 75 mg/die; (3) bisoprolol 5 mg QD; (4) irbesartan 150 mg QD; (5) fenofibrate 145 mg QD; and (6) omeprazole 20 mg QD. The pharmacological therapy changed at patients' discharge to the following: (1) aspirin lysine 75 mg QD; (2) clopidogrel sulfate 75 mg/die; (3) bisoprolol 5 mg QD; (4) irbesartan 150 mg QD; (5) atorvastatin 20 mg QD; and (6) ranitidine 150 mg BID.
Twenty-eight months later, a coronary angiography performed because of a novel effort angina showed a 70% intrascaffold restenosis (Figure 2A and 2B ). Intracoronary imaging with 3D optical coherence tomography (Illumien Optis, St. Jude Medical) confirmed a critical restenosis because of extensive finely textured neointimal thickening, with a high backscatter in most areas, whereas a heterogeneous and layered aspect in some areas could suggest ongoing evolution to neoatherosclerosis ( Figure 2C and 2D) . Surprisingly, most of the strut remnants still showed the open box appearance ( Figure 2C and 2D). However, some struts showed a more advanced degree of degradation (dissolved black box) at the level of major neointimal hyperplasia ( Figure 2C-2D ). Because the dissolved black box remnants colocalized with the area of maximal neointimal thickening, we cannot exclude that this morphological pattern might be related to the occurrence of restenosis.
Drug-eluting stents were proven highly effective in preventing neointimal proliferation. 1 As an emerging and attractive breakthrough technology, BVS is expected to maintain a similar efficacy toward prevention of restenosis while allowing restoration of vessel physiology. Although a 6% 2-year target lesion revasularization (TLR) rate has been recently reported, no conclusive data on the underlying mechanism(s) are yet available. 4 To the best of our knowledge, this is the first comprehensive intracoronary imaging report of BVS restenosis, including 3D optical coherence tomography, showing ominous neointimal proliferation causing significant restenosis.
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C. Indolfi reports educational and research grants from Abbott. The other authors report no conflicts. C and D, Cross-sectional aspect of the finely textured neointimal thickening, with a high backscatter, responsible for the restenosis (the green line indicates the lumen profile). The magnified boxes with the * symbols show the particular of strut remnants with the open box appearance. The magnified boxes with the # symbols show the particular of strut remnants with the dissolved black box appearance. A video clip od the PCT imaging is available as supplementary on-line material. E, 3D optical coherence tomographic reconstruction of the scaffolded segment shows neointimal proliferation above the BVS struts in the proximal portion of the scaffold (right). F and G, Longitudinal aspect of the restenotic lesion in the lumen profile mode (F) and in the classical L mode (G). It is evident that the reduction of the internal lumen area is related to in-scaffold neointimal proliferation.
